¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ T315I º¯ÀÌ°¡ÀÖ´Â Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ¹éÇ÷º´ÀÇ Ponatinib Ä¡·á vs. µ¿Á¾Áٱ⼼Æ÷À̽ÄÀÇ »ýÁ¸À² ºñ±³
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

T315I º¯ÀÌ°¡ÀÖ´Â Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ¹éÇ÷º´(Philadelphia chromosome-positive leukemias)¿¡¼­ÀÇ ponatinib vs. µ¿Á¾Áٱ⼼Æ÷ À̽ÄÀÇ Àü¹ÝÀûÀÎ »ýÁ¸À² ºñ±³

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation



 

¿¬±¸¸ñÀû


 

Æ®·¹¿À´Ñ - À̼ҷçÀ̽Š315 (T315I) µ¹¿¬º¯ÀÌ°¡ ÀÖ´Â ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ (chronic myeloid leukemia , CML), ¶Ç´Â Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º¹éÇ÷º´(Philadelphia chromosome-positive leukemias, Ph+) ±Þ¼º ¸²ÇÁ ±¸¼º ¹éÇ÷º´ (acute lymphoblastic leukemia, ALL) ȯÀÚÀÇ È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀº ¾ÆÁ÷±îÁö °ÅÀÇ ¾Ë·ÁÁöÁö ¾Ê°íÀÖ´Ù. ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº CML ȯÀÚ¿Í Ph + ALL ȯÀÚÀÇ ponatini Ä¡·á¿Í allogeneic stem cell transplantation (allo-SCT) Ä¡·á¸¦ ºñ±³ÇÏ¿© Àü¹ÝÀûÀÎ »ýÁ¸À² (OS)À» Æò°¡Çϱâ À§ÇÔÀÌ´Ù.




 

[±Ù°Å±â¹Ý ÀÓ»óÁú¹® ¿ä¾à]  


 

ÀÓ»óÁú¹®

Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º¹éÇ÷º´(Philadelphia chromosome-positive leukemias, Ph+) ȯÀÚ¿¡°Ô Æ÷³ªÆ¼´Õ(Ponatinib) vs µ¿Á¾Áٱ⼼Æ÷À̽Ä( allogeneic stem cell transplantation, allo-SCT) Ä¡·á¿¡¼­ »ýÁ¸À²ÀÇ Â÷ÀÌ°¡ ÀÖ½À´Ï±î?

±Ù°Å±â¹Ý ´äº¯

T315I ¾ç¼º CP-CML ȯÀÚÀÇ »ýÁ¸ ±â°£ ¿¬ÀåÀ» À§ÇÏ¿©, Ponatinib Ä¡·á¸¸À¸·Î À̽Ŀ¡ ´ëÇÏ¿© À¯¿ëÇÑ ´ë¾ÈÀÌ´Ù

¼­ÁöÁ¤º¸

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug 1;123(15):2875-2880. doi: 10.1002/cncr.30558

¿¬±¸¸ñÀû

Æ÷³ªÆ¼´Õ(Ponatinib) vs µ¿Á¾Áٱ⼼Æ÷À̽Ä(allo-SCT) Ä¡·áÀÇ Àü¹ÝÀû »ýÁ¸À² Â÷ÀÌ ºñ±³

¿¬±¸¼³°è

ºñ¹«ÀÛÀ§ ÅëÁ¦¿¬±¸(Non-randomised controlled trial)

¿¬±¸´ë»ó

¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML) ¶Ç´Â Çʶóµ¨ÇÇ¾Æ ¾ç¼º (Ph +) ±Þ¼º ¸²ÇÁ ±¸¼º ¹éÇ÷º´(ALL) Áø´ÜÀ» ¹ÞÀº ȯÀÚ 184¸í, (N=184)

½ÃÇ豺 ÁßÀç

Ponatinib therapy group (n=128)  

´ëÁ¶±º ÁßÀç

Allo?SCT therapy group (n=56)

Æò°¡ÁöÇ¥

Àü¹ÝÀûÀÎ »ýÁ¸·ü(Overall survival, OS)

ÁÖ¿ä°á°ú

Æù³ªÆ¼´Õ(ponatinib)À» Åõ¿©¹ÞÀº CP-CML ȯÀÚ±ºÀº allo?SCT ȯÀÚ±º¿¡ ºñÇØ 24°³¿ù°ú 48°³¿ù¿¡¼­ »ýÁ¸·üÀÌ ÀǹÌÀÖ°Ô ³ô¾Ò´Ù. (24°³¿ù : 84 % vs 60.5 %, P = .004; 48°³¿ù : 72.7 % vs 55.8 %, P = .013, HR= 0.37 (95% confidence interval= 0.16?0.84; P = .017).

±Ù°Å¼öÁØ

Moderate

ÀÛ¼ºÀÚ

ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)

Copyright © 2015. Medical Research Information Center (MedRIC) Editors



 

¿¬±¸°á°ú


 

±×¸² 1) Adjusted overall survival analysis is illustrated for patients who received treatment with ponatinib (solid line) or underwent stem cell transplantation (allo?SCT) (dashed line) stratified by phase. (A) Chronic?phase chronic myeloid leukemia (CML), (B) accelerated?phase CML, (C) blast?crisis CML, and (D) Philadelphia chromosome?positive acute lymphoblastic leukemia are illustrated. Patients were censored at the end of follow?up or at the end of the study, whichever occurred first. Kaplan?Meier curves were adjusted by standardizing each treatment group sample to the characteristics of the combined study population. P values comparing adjusted overall survival were computed at the 48?month mark using log?rank tests. The numbers of patients at risk at each 12?month interval are indicated below the corresponding figure and were obtained from adjusted Kaplan?Meier curves weighted by stabilized inverse probability of treatment weights. (Source: Cancer. 2017 Aug 1;123(15):2875-2880. doi: 10.1002/cncr.30558)



 

Ãâó :

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug 1;123(15):2875-2880.


 

Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2014 May; 74(7):793-806.


 


2018-12-03 ¿ÀÈÄ 1:00:40, Á¶È¸¼ö : 1974